BOLT vs LIN · rev $7.7M vs P/E 34, rev $33.99B
Bolt Biotherapeutics (BOLT) versus Linde plc Ordinary Shares (LIN) — a side-by-side from cached financials, not a winner call.
Bolt Biotherapeutics (BOLT) is a biotechnology company listed on US.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
Latest reported BOLT revenue for 2024-12-31 was $7.7M. Net income was -$63.1M. Revenue was down 2.4% from 2023-12-31 to 2024-12-31. BOLT currently screens at market cap $11.3M.
Latest reported LIN revenue for 2025-12-31 was $33.99B. Net income was $6.90B. Revenue was up 3.0% from 2024-12-31 to 2025-12-31. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
BOLT currently screens at market cap $11.3M. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Not investment advice. Open the BOLT and LIN stock pages for the full models.
Not investment advice.